CA2419274A1 - Methods and compositions for treating ige-related disease using nnt-1 inhibitors - Google Patents

Methods and compositions for treating ige-related disease using nnt-1 inhibitors Download PDF

Info

Publication number
CA2419274A1
CA2419274A1 CA002419274A CA2419274A CA2419274A1 CA 2419274 A1 CA2419274 A1 CA 2419274A1 CA 002419274 A CA002419274 A CA 002419274A CA 2419274 A CA2419274 A CA 2419274A CA 2419274 A1 CA2419274 A1 CA 2419274A1
Authority
CA
Canada
Prior art keywords
nnt
ige
binding agent
selective binding
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002419274A
Other languages
English (en)
French (fr)
Inventor
Giorgio Senaldi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2419274A1 publication Critical patent/CA2419274A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002419274A 2000-08-18 2001-08-17 Methods and compositions for treating ige-related disease using nnt-1 inhibitors Abandoned CA2419274A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22643600P 2000-08-18 2000-08-18
US60/226,436 2000-08-18
US09/931,704 US6849260B2 (en) 2000-08-18 2001-08-16 Methods and compositions for treating IgE-related disease using NNT-1 inhibitors
US09/931,704 2001-08-16
PCT/US2001/025906 WO2002015977A2 (en) 2000-08-18 2001-08-17 Methods and compositions for treating ige-related disease using nnt-1 inhibitors

Publications (1)

Publication Number Publication Date
CA2419274A1 true CA2419274A1 (en) 2002-02-28

Family

ID=26920541

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002419274A Abandoned CA2419274A1 (en) 2000-08-18 2001-08-17 Methods and compositions for treating ige-related disease using nnt-1 inhibitors

Country Status (7)

Country Link
US (1) US6849260B2 (cg-RX-API-DMAC7.html)
EP (1) EP1309374A2 (cg-RX-API-DMAC7.html)
JP (1) JP2004513081A (cg-RX-API-DMAC7.html)
AU (2) AU2001283451A1 (cg-RX-API-DMAC7.html)
CA (1) CA2419274A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA03001434A (cg-RX-API-DMAC7.html)
WO (1) WO2002015977A2 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006076288A2 (en) * 2005-01-11 2006-07-20 Five Prime Therapeutics, Inc. Dna constructs for long-term expression of intravascularly injected naked dna

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT787491E (pt) 1994-10-17 2000-11-30 Aventis Pharma Ltd Composicao para a profilaxia e para o tratamento de doencas alergicas de tipo i
DE69633623T2 (de) 1995-07-17 2005-12-01 Medivir Uk Ltd. Cystein-Protease-Inhibitoren für die Behandlung von allergischen Krankheiten verursacht duch IgE
ATE273391T1 (de) 1997-02-03 2004-08-15 Amgen Inc Neurotrophischer faktor nnt-1
US5741772A (en) 1997-02-03 1998-04-21 Amgen Inc. Neurotrophic factor NNT-1
EP1001982A1 (en) 1997-06-30 2000-05-24 Human Genome Sciences, Inc. Cardiotrophin-like cytokine
GB9913327D0 (en) 1999-06-08 1999-08-11 Smithkline Beecham Biolog Vaccine

Also Published As

Publication number Publication date
EP1309374A2 (en) 2003-05-14
US6849260B2 (en) 2005-02-01
AU2005232321A1 (en) 2005-12-01
WO2002015977A3 (en) 2002-11-28
MXPA03001434A (es) 2004-12-13
US20020041873A1 (en) 2002-04-11
JP2004513081A (ja) 2004-04-30
WO2002015977A2 (en) 2002-02-28
AU2001283451A1 (en) 2002-03-04

Similar Documents

Publication Publication Date Title
US6562333B1 (en) Purified mammalian CTLA-8 antigens and related reagents
US20060177436A1 (en) Methods for Treating Autoimmune Disorders
JP2008529529A (ja) 抗インターフェロンアルファモノクローナル抗体及び使用方法
PL180125B1 (pl) Bialko fuzyjne o swoistosci wiazania przeciwko ludzkiej IL-4, PL PL PL PL PL PL
KR20090091181A (ko) 자가면역 장애의 치료를 위한 티로신 수용체 키나아제 ｂ 작용제
CN105408355A (zh) 用于提高免疫球蛋白a水平的方法
JP2000514295A (ja) 哺乳動物のケモカイン試薬
JP2009280620A (ja) 哺乳動物ランゲルハンス細胞抗原に対する抗体およびそれらの使用
KR20110011676A (ko) 항-ＰｉｒＢ 항체
WO1997003691A1 (en) Methods of treatment of neurological diseases by interferon antagonists
JP4864278B2 (ja) 脱髄疾患を処置する方法
WO1995020604A1 (en) Antibodies to mammalian natural killer antigens and uses
AU2001288286A1 (en) Methods for treating demyelinating diseases
US6849260B2 (en) Methods and compositions for treating IgE-related disease using NNT-1 inhibitors
ES2301164T3 (es) Slam, antigeno coestimulador de la superficie de celulas t.
JP2000511418A (ja) ヒトインターロイキン―１ｊおよびそのアンタゴニスト
JP2002514067A (ja) 神経栄養因子ｎｎｔ−１
US20040219149A1 (en) Methods for the modulation of il-13
US6824781B2 (en) Method of impairing movement of a CLA + memeory T-cell within or to the skin of a mammal by administering a CTACK antagonist
US6762341B2 (en) Uses of mammalian CCR8 receptors and related reagents
US20040096446A1 (en) Methods for treating demyelinating diseases
WO1995002611A1 (en) Cell surface protein present on nk (natural killer cells) named dx1
MXPA06006377A (es) Metodos para modular la actividad de citocina y reactivos relacionados.
JP2006513187A (ja) タキソール誘発性感覚性ニューロパシーを処置するための方法
KR101268562B1 (ko) Ｔｌｔ-6 단백질에 대한 항체 및 그 응용

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued